A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Summary

A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)

Timeline

Start

2023-08-29

Primary completion

2025-08-02

Completion

2025-08-28

Outcome

Outcome not reported

Stopped (Business): “Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons.”

Drugs

Indications